Should I Buy NEO? NEO 2026 Analysis

Should You Buy Neogenomics Inc (NEO) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

11.420

1 Day change

1.33%

52 Week Range

14.730

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient entry: price is breaking below near-term support while momentum (MACD) is still deteriorating.
Short-term setup is oversold and could bounce, but there’s no proprietary buy signal (AI Stock Picker/SwingMax) to justify treating this as a high-conviction immediate entry.
Best stance today: Hold / avoid new buys until price reclaims ~$11.75–$12.36 (S1/pivot) or momentum improves.

Technical Analysis

Trend/Momentum: MACD histogram at -0.139 and negatively expanding = bearish momentum still strengthening.
RSI: RSI(6) at ~26.4 = oversold conditions; a bounce is possible, but oversold alone is not a trend reversal.
Moving averages: Converging MAs = indecision, not a confirmed uptrend.
Key levels: Current $11.59 is below S1 $11.754 and near S2 $11.379 (next downside support). Overhead resistance/pivot at $12.361, then $12.969.
Pattern-based odds (provided): Next month skew negative (-3.15% expectation), suggesting rallies may be sold until trend improves.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning/Sentiment: Extremely low put/call ratios (OI 0.21, volume 0.01) = options market is call-heavy / bullishly positioned.
Volatility: 30D IV ~86% vs historical vol ~41%, with IV percentile ~84.9 = options are pricing elevated moves (often seen into catalysts).
Activity: Total volume is small (133 contracts; puts only 1), so the bullish read is more about skew than heavy conviction.
Catalyst timing: Earnings 2026-02-17 pre-market likely contributes to elevated IV.

Technical Summary

Sell

Buy

Positive Catalysts

- Options skew is strongly call-leaning, suggesting traders are positioned for upside.

Neutral/Negative Catalysts

- Technical damage ongoing: bearish MACD expansion and price trading below S1 indicates weak near-term control by buyers.
- Gross margin pressure: latest reported gross margin down YoY, which can weigh on quality-of-growth narrative.
- No supportive near-term news flow in the last week to change sentiment or reverse the tape.
- Near-term probabilities provided skew negative over the next month (pattern-based expectation).

Financial Performance

Latest quarter provided: 2025/Q3
Revenue: $187.8M, +11.9% YoY (solid top-line growth).
Profitability trend: Net income -27.1M, improved +53.3% YoY (loss narrowing).
EPS: -0.21, improved +50% YoY (still negative but trending better).
Margins: Gross margin 42.84%, down ~4.0% YoY (key watch item: growth is improving but efficiency/mix is pressuring margin).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent actions trend: price targets have been raised across multiple firms.
TD Cowen (2026-01-07): Buy, PT $16 (raised from $14).
BofA (2025-12-15): Neutral, PT $13 (raised from $11).
Piper Sandler (2025-11-10): Overweight, PT $12 (raised from $11).
Wall Street pros: improving targets, expectation of better sector fundamentals into 2026, and continued revenue growth.
Wall Street cons: still loss-making and margin compression; one major firm remains Neutral, reflecting execution sensitivity.

11 Analyst Rating

Wall Street analysts forecast NEO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NEO is 14 USD with a low forecast of 12 USD and a high forecast of 16 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

6 Hold

0 Sell

Moderate Buy

Current: 11.270

Low

Averages

High

Current: 11.270

Low

Averages

High

TD Cowen

Dan Brennan

Buy

maintain

$14 -> $16

AI Analysis

2026-01-07

Reason

TD Cowen

Dan Brennan

Price Target

$14 -> $16

AI Analysis

2026-01-07

maintain

Buy

Reason

TD Cowen analyst Dan Brennan raised the firm's price target on NeoGenomics to $16 from $14 and keeps a Buy rating on the shares. The firm adjusted targets in the diagnostics group as part of a Q4 preview. It expects solid results and 2026 outlooks for the sector, saying strong fundamentals remain.

BofA

Neutral

maintain

$11 -> $13

2025-12-15

Reason

BofA

Price Target

$11 -> $13

2025-12-15

maintain

Neutral

Reason

BofA raised the firm's price target on NeoGenomics to $13 from $11 and keeps a Neutral rating on the shares. The firm is updating it price targets for Life Sciences & Diagnostic Tools stocks under its coverage, the analyst tells investors. Headwinds are expected to fade, and markets are expected to normalize in 2026, firm adds. The firm believes the biggest upside for the sector will be a return to spending by Biopharma, leading BofA to favor companies with higher exposure to research and development.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NEO

Unlock Now

NEO Should I Buy

NEO Should I Buy

Should You Buy Neogenomics Inc (NEO) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch